[
  {
    "ts": "2026-01-23T06:30:00+00:00",
    "headline": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
    "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
    "url": "https://www.barrons.com/articles/abbvie-dodged-a-patent-disaster-and-shares-gained-460-merck-and-bristol-myers-are-next-5968f3cd?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ff057859-25cc-38ab-bf6d-78ba37dc9314",
      "content": {
        "id": "ff057859-25cc-38ab-bf6d-78ba37dc9314",
        "contentType": "STORY",
        "title": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
        "description": "",
        "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
        "pubDate": "2026-01-23T06:30:00Z",
        "displayTime": "2026-01-23T06:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ff057859-25cc-38ab-bf6d-78ba37dc9314/abbvie-dodged-a-patent.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/90655360b7a4e125d540f8474523bc7f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6BytADf.wdgQOFbGSuj0IA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/90655360b7a4e125d540f8474523bc7f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aiR.2Irm6EXEA73p_uJuJQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/90655360b7a4e125d540f8474523bc7f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/abbvie-dodged-a-patent-disaster-and-shares-gained-460-merck-and-bristol-myers-are-next-5968f3cd?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T12:18:00+00:00",
    "headline": "JANX Enters Global Oncology Collaboration With BMY, Stock Rises",
    "summary": "Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.",
    "url": "https://finance.yahoo.com/news/janx-enters-global-oncology-collaboration-121800601.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "5c5166dc-2f20-345c-aa13-6c0aad1e21ef",
      "content": {
        "id": "5c5166dc-2f20-345c-aa13-6c0aad1e21ef",
        "contentType": "STORY",
        "title": "JANX Enters Global Oncology Collaboration With BMY, Stock Rises",
        "description": "",
        "summary": "Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.",
        "pubDate": "2026-01-23T12:18:00Z",
        "displayTime": "2026-01-23T12:18:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhUbp770QgvNMyXdM9XKnA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ii2rwaxi8Dao2zrk4I.W2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/janx-enters-global-oncology-collaboration-121800601.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/janx-enters-global-oncology-collaboration-121800601.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T15:11:22+00:00",
    "headline": "A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results",
    "summary": "Bristol Myers Squibb (BMY) is back in focus after two key updates: a new AI lung cancer screening agreement with Microsoft, and positive Phase 3 data for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy. See our latest analysis for Bristol-Myers Squibb. Those AI and cardiology updates come after a busy start to 2026, including oncology focused deals like the new Janux Therapeutics agreement. They follow a 90 day share price return of 25.35% against a weaker 1 year total...",
    "url": "https://finance.yahoo.com/news/look-bristol-myers-squibb-bmy-151122303.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "1716787b-8b41-3a6a-a86d-b0c8c6b59602",
      "content": {
        "id": "1716787b-8b41-3a6a-a86d-b0c8c6b59602",
        "contentType": "STORY",
        "title": "A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results",
        "description": "",
        "summary": "Bristol Myers Squibb (BMY) is back in focus after two key updates: a new AI lung cancer screening agreement with Microsoft, and positive Phase 3 data for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy. See our latest analysis for Bristol-Myers Squibb. Those AI and cardiology updates come after a busy start to 2026, including oncology focused deals like the new Janux Therapeutics agreement. They follow a 90 day share price return of 25.35% against a weaker 1 year total...",
        "pubDate": "2026-01-23T15:11:22Z",
        "displayTime": "2026-01-23T15:11:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/look-bristol-myers-squibb-bmy-151122303.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/look-bristol-myers-squibb-bmy-151122303.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "JANX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T18:05:00+00:00",
    "headline": "Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?",
    "summary": "Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.",
    "url": "https://www.fool.com/investing/2026/01/23/forget-eli-lilly-buy-these-unstoppable-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "d36fc022-2457-3be0-9329-dd797eed60e8",
      "content": {
        "id": "d36fc022-2457-3be0-9329-dd797eed60e8",
        "contentType": "STORY",
        "title": "Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?",
        "description": "",
        "summary": "Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.",
        "pubDate": "2026-01-23T18:05:00Z",
        "displayTime": "2026-01-23T18:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/e6e25b0076ab1d65c4645d933a1ffa84",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A hand drawing a scale showing price vs. value.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oH1vMW9a8lQPyVxDdje.yQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/e6e25b0076ab1d65c4645d933a1ffa84.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pM7HlYM_F0inHleq4d2DMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/e6e25b0076ab1d65c4645d933a1ffa84.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/23/forget-eli-lilly-buy-these-unstoppable-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/forget-eli-lilly-buy-unstoppable-180500495.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T20:06:45+00:00",
    "headline": "Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline Developments",
    "summary": "If you are wondering whether Bristol-Myers Squibb is offering good value at around US$54.94 per share, you are not alone. Many investors are asking the same question right now. The stock has had mixed returns, with a 3% decline over the last 7 days, a 1.2% gain over the last 30 days, a 2.8% gain year to date, and a 2.4% decline over the last year. The 3-year and 5-year returns sit at a 13.7% decline and a 7.6% gain respectively. Recent headlines around Bristol-Myers Squibb have focused on...",
    "url": "https://finance.yahoo.com/news/reassessing-bristol-myers-squibb-bmy-200645146.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "bf2c1afd-5cfd-3509-92e5-81354b74a049",
      "content": {
        "id": "bf2c1afd-5cfd-3509-92e5-81354b74a049",
        "contentType": "STORY",
        "title": "Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline Developments",
        "description": "",
        "summary": "If you are wondering whether Bristol-Myers Squibb is offering good value at around US$54.94 per share, you are not alone. Many investors are asking the same question right now. The stock has had mixed returns, with a 3% decline over the last 7 days, a 1.2% gain over the last 30 days, a 2.8% gain year to date, and a 2.4% decline over the last year. The 3-year and 5-year returns sit at a 13.7% decline and a 7.6% gain respectively. Recent headlines around Bristol-Myers Squibb have focused on...",
        "pubDate": "2026-01-23T20:06:45Z",
        "displayTime": "2026-01-23T20:06:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/reassessing-bristol-myers-squibb-bmy-200645146.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/reassessing-bristol-myers-squibb-bmy-200645146.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]